Stilla Technologies Secures $26.5 Million in Series C Funding for Revolutionary Genetic Testing Solutions

Stilla Technologies is thrilled to announce the successful raising of $26.5 million in a recent funding round, a significant boost that will further enhance its mission of transforming genetic testing across various applications. As a prominent player in the biotechnology sector, Stilla Technologies stands at the forefront of innovation with its advanced Multiplex Crystal Digital PCR™ technology. This cutting-edge solution enables researchers and clinicians to conduct high-resolution genetic analysis with unparalleled accuracy and efficiency. With the naica® system, users benefit from a highly sensitive platform that streamlines the entire dPCR process onto a single chip, offering fast results through an easy workflow and intuitive software. The strategic funding will be directed towards expanding Stilla’s R&D efforts, enhancing its product offerings, and accelerating the development of new applications aimed at revolutionizing cancer research, liquid biopsy studies, infectious disease diagnostics, and wastewater testing. Stilla’s pioneering work in developing the world’s first 6-color Digital PCR platform will now be amplified, making Digital PCR a standard tool within the life sciences community. This funding marks a pivotal moment for Stilla as it continues to push the boundaries of genetic analysis and aims to democratize accessibility to advanced diagnostic technologies across diverse research and therapeutic fields. For more information on Stilla Technologies and its revolutionary products, visit our website and connect with us on Twitter @StillaTech.